World Library  
Flag as Inappropriate
Email this Article

Nicholas Lydon

 

Nicholas Lydon

Nicholas Lydon
Born (1957-02-27) February 27, 1957 (age 57)
Institutions Amgen
Schering-Plough
Ciba-Geigy
Alma mater University of Leeds (undergraduate)
University of Dundee (postgraduate)
Thesis (1982)
Known for Gleevec
AnaptysBio
BluePrint Medicines
Notable awards Lasker Clinical Award (2009)
Japan Prize (2012)
Fellow of the Royal Society (2013)
Website

Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur.[1] In 2009 he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML); converting a fatal cancer into a manageable chronic condition.[2][3][4][5] [6][7]

Education

Lydon was educated at Strathallan School near Perth, Scotland.[8] He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his Ph.D in biochemistry from the University of Dundee, Scotland in 1982.[9][8]

Career

In 1982 Lydon accepted a position with Schering-Plough based in France as Charge de Recherche.[3] Three years later he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec.[8] In 1997 he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002.[8] Thereafter, he established several companies that continue to develop drugs to treat various conditions.[8]

Honours and awards

References

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.